作者：王秋桐1 ，吴爽 1 ，曹婷婷 1 ，赵瑞 2

单位：

1.061001 河北省沧州市，沧州医学高等专科学校2.100050 北京市，首都医科大学北京朝阳医院

Units：

1.Cangzhou Medical College?Hebei?China，Cangzhou 061001，China2.Beijing Chaoyang Hospital，Capital Medical University，Beijing 100050，China

关键词：

癌，非小细胞肺；劳拉替尼；分子靶向治疗；治疗结果；安全性；临床研究；综述

Keywords：

Carcinoma，non-small-cell lung；Lorlatinib；Molecular targeted therapy；Treatment outcome；Safety；Clinical research；Review

CLC：

DOI：

10.12114/j.issn.1008-5971.2021.00.005

Funds：

摘要：

劳拉替尼是第三代强效、高靶向性的新型间变性淋巴瘤激酶（ALK）/c-ros 肉瘤致癌因子 - 受体酪氨酸激酶（ROS1）双重抑制剂。与克唑替尼、阿来替尼等前两代 ALK 抑制剂相比，劳拉替尼对 ALK 阳性（ALK + ）肿瘤细胞和多个基因突变点有较好的抑制作用。多项临床研究指出，劳拉替尼二线治疗经第一代或第二代 ALK 抑制剂治疗后病情进展或耐药的 ALK + 转移性非小细胞肺癌（NSCLC）患者具有良好的抗肿瘤活性、颅内治疗效果和安全性。本文重点对劳拉替尼治疗晚期 NSCLC 的临床疗效、安全性及未来发展趋势进行综述，以期为临床用药提供参考。

Abstract：

Lorlatinib is a third-generation，powerful and highly targeted new type of anaplastic lymphoma kinase （ALK）/c-ros sarcoma oncogenic factor-receptor tyrosine kinase（ROS1）dual inhibitor.Compared with the previous two generation inhibitors，such as Crizotinib and Alectinib，Lorlatinib has a better inhibitory effect on ALK positive（ALK + ）tumor cells and multiple gene mutation points.Several clinical trials have approved that the second-line treatment of Loratinib has good anti-tumor activity，intracranial therapeutic effect and safety in patients with ALK + metastatic non-small cell lung cancer（NSCLC）who have progressed or resisted after receiving the first or second generation ALK inhibitors treatment.This article emphatically reviewed the clinical efficacy，safety and future development trends of Lolatinib in the treatment of advanced NSCLC，in order to provide reference for clinical medication.

ReferenceList：